Cellectar Biosciences reports 79.2% major response rate in Phase 2 CLOVER-WaM iopofosine I 131 analysis after BTK inhibitors

• Cellectar BioSciences flagged new Phase 2 CLOVER-WaM subset results for iopofosine I 131 in BTK inhibitor-refractory Waldenström macroglobulinemia.
• Findings will be presented Oct. 15, 2026 at the International Workshop for Waldenström Macroglobulinemia in Palm Springs, California.
• The analysis showed strong tumor response with durable benefit in heavily pretreated patients treated immediately following BTK inhibitor therapy.
• Management kept plans to start a Phase 3 confirmatory trial in early 2027.
• The company targets a U.S. accelerated-approval filing in 1H27, citing Breakthrough Therapy Designation and a potential end-2027 decision timeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290730PRIMZONEFULLFEED9835571) on September 29, 2026, and is solely responsible for the information contained therein.